Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Oxaliplatin in Metastatic Breast Cancer
NCT00204776Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Mar 2005
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, oxaliplatin in breast cancer, sponsored by University of Wisconsin–Madison. Started Mar 2005; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00204776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00204776.